Business Development Deal Architecture
  • Search OnBioBD:

  • OnBioBD OldSkool NEWS:

    - OnBioVC 4Q11 Trend Analysis, now available
    - OnBioVC 1Q12 White Paper, now available
    - OnBioVC 1Q12 Trend Analysis, coming soon

  • FDA Registered Contract Manufacturer

NanoBio (Ann Arbor, MI), a clinical-stage biotechnology company focused on anti-infective intranasal & intramuscular vaccines for influenza, closed an $11M Series C financing. Participants include Perseus and Venture Investors.

Rib-X Pharmaceuticals (New Haven, CT), a clinical-stage pharmaceutical company developing next-generation antibiotics, closed an $18.7M Series B financing. Participants include Vatera Healthcare Partners, Warburg Pincus, ABS Ventures and Vox Equity Partners.

ImmuneXcite (Watertown, MA) a development-stage biopharmaceutical company focused on a therapeutic platform for the development of monoclonal antibodies and vaccines for cancer and infectious diseases, closed a $2.4M Series A financing. Participants include Boston Harbor Angels.

CrystalGenomics (Korea) a clinical-stage biopharmaceutical company focused on chemoproteomics based drug discovery company working on an NSAID, antibiotics for MRSA and HIF inhibitors for hypoxia, therapeutics for cancer, closed a third tranche of $2.6M Series A financing bringing the total round to $20M. Participants include Korea Seoul Life Sciences Fund, Hanwha Venture Capital and Oxford […]

ImmuneXcite (Watertown, MA) a development-stage biopharmaceutical company focused on a therapeutic platform for the development of monoclonal antibodies and vaccines for cancer and infectious diseases, closed a $2.4M Series A financing. Participants include Boston Harbor Angels.

Viroblock (Switzerland) a development-stage biotechnology company focused on anti-viral fabric and air filtration technology for prevention of influenza and SARS, closed a $3.6M Series C financing. Participants include StartAngels Network.

Topica Pharmaceuticals (Palo Alto, CA) a clinical-stage pharmaceutical company focused on treatments for onychomycosis, closed a $27M Series B financing. Participants include Third Rock Ventures, Prospect Venture Partners and Yasuda Enterprise Development Corporation.

Groove Biopharma (Seattle, WA) a development-stage biopharmaceutical company focused on microRNA therapeutics for cancer, fibrosis and infectious disease, closed a $6M Series B financing. Participants include Amgen Ventures, Versant Ventures, Alexandria Real Estate Equities, ARCH Venture Partners, OVP Venture Partners and WRF Capital.

Atox Bio (Israel) a clinical-stage biotechnology company focused on small molecules for the treatment of severe bacterial infections, sepsis, necrotizing soft tissue infections and intra-abdominal infections, closed a $3.25M Series A financing. Participants include Esperante.

Excelimmune (Woburn, MA) a preclinical-stage biopharmaceutical company focused on a recombinant polyclonal antibody platform for the treatment of infectious disease, closed a $12M Series C financing. Participants were not identified.

Affinium Pharmaceuticals (Austin, TX) a clinical-stage specialty pharmaceutical company focused on small molecule antibiotics targeting staph and MRSA infections, closed a $15M Series B financing. Participants include SV Life Sciences, Genesis Capital Partners, Forward Ventures and Ontario Emerging Technologies Fund. Thanx for your patience as we catch-up.

Theraclone Sciences (Seattle, WA) a preclinical-stage biopharmaceutical company focused on monoclonal antibodies for infectious disease and inflammation, closed a $10.6M Series B, bringing the total round to $41M. Participants include Arch Venture Partners, Canaan Partners, MPM Capital, Healthcare Ventures, Alexandria Real Estate Equities, Amgen Ventures and Zenyaku Kogyo.

Excelimmune (Woburn, MA) a preclinical-stage biopharmaceutical company focused on a recombinant polyclonal antibody platform for the treatment of infectious disease, closed a $10.5M Series B financing. Participants were not identified.

« Previous Entries  Next Page »

to top of page...